{"id":745114,"date":"2015-09-27T06:00:00","date_gmt":"2015-09-27T06:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-data-from-keynote-028-mercks-trial-evaluating-keytruda-pembrolizumab-across-a-range-of-cancer-types-presented-at-2015-european-cancer-congress\/"},"modified":"2025-11-07T01:24:55","modified_gmt":"2025-11-07T06:24:55","slug":"new-data-from-keynote-028-mercks-trial-evaluating-keytruda-pembrolizumab-across-a-range-of-cancer-types-presented-at-2015-european-cancer-congress","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-data-from-keynote-028-mercks-trial-evaluating-keytruda-pembrolizumab-across-a-range-of-cancer-types-presented-at-2015-european-cancer-congress\/","title":{"rendered":"New Data from KEYNOTE-028, Merck\u2019s Trial Evaluating KEYTRUDA\u00ae (pembrolizumab) Across a Range of Cancer Types, Presented at 2015 European Cancer Congress"},"content":{"rendered":"<p class=\"bwalignc\">       Findings Show Anti-Tumor Activity for KEYTRUDA in Two        Gastrointestinal Cancers     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced new findings from the KEYNOTE-028 Phase 1b study, the<br \/>\n      clinical trial investigating the use of the company\u2019s anti-PD-1 therapy,<br \/>\n      KEYTRUDA<sup>\u00ae<\/sup> (pembrolizumab) in multiple, difficult-to-treat<br \/>\n      cancers. Data from this trial, to be presented at the European Cancer<br \/>\n      Congress (ECC) in Vienna, Austria, Sept. 25-29, include the first-time<br \/>\n      findings for KEYTRUDA in two gastrointestinal cancers, advanced anal<br \/>\n      cancer and advanced biliary tract cancer, and add to Merck\u2019s growing<br \/>\n      body of clinical data for KEYTRUDA.\n    <\/p>\n<p>\n      KEYNOTE-028 is an ongoing multi-cohort, non-randomized Phase 1b basket<br \/>\n      trial \u2013 a trial design that allows for the study of multiple<br \/>\n      sub-populations of different tumor or histological types within one<br \/>\n      study. The study is evaluating the safety, tolerability, and anti-tumor<br \/>\n      activity of KEYTRUDA monotherapy (10 mg\/kg dosed every two weeks) in<br \/>\n      more than 450 patients across 20 different types of cancer. The study<br \/>\n      was designed to evaluate patients with advanced solid tumors that<br \/>\n      express PD-L1 and which have not responded to current therapy or for<br \/>\n      which current therapy is not appropriate.\n    <\/p>\n<p>\n      \u201cThrough innovative trials like KEYNOTE-028, we are advancing our<br \/>\n      understanding of the potential benefit of KEYTRUDA in a wide range of<br \/>\n      difficult-to-treat cancers,\u201d said Dr. Roger Dansey, senior vice<br \/>\n      president and therapeutic area head, oncology late-stage development,<br \/>\n      Merck Research Laboratories. \u201cMerck is committed to evaluating KEYTRUDA<br \/>\n      across as many tumor types as possible and the expansion of our clinical<br \/>\n      development program over the years reflects this. We are encouraged by<br \/>\n      these early stage data, and will continue to advance KEYTRUDA in order<br \/>\n      to deliver on our goal of helping as many people with cancer as<br \/>\n      possible.\u201d\n    <\/p>\n<p>\n      The KEYTRUDA clinical development program has rapidly expanded to<br \/>\n      encompass more than 30 tumor types in more than 130 clinical trials, of<br \/>\n      which more than 70 trials combine KEYTRUDA with other cancer treatments.<br \/>\n      Registration-enabling trials of KEYTRUDA monotherapy are currently<br \/>\n      enrolling patients in melanoma, non-small cell lung cancer (NSCLC), head<br \/>\n      and neck cancer, bladder cancer, gastric cancer, colorectal cancer, and<br \/>\n      Hodgkin Lymphoma, with further trials in planning for other cancers.\n    <\/p>\n<p>\n      <b>Early Findings from Advanced Squamous Cell Carcinoma (SCC) of the<br \/>\n      Anal Canal (Abstract #500)<\/b>\n    <\/p>\n<p>\n      Early findings from 25 heavily pre-treated patients with advanced anal<br \/>\n      cancer \u2013 to be presented in an oral session on Sunday, Sept. 27 by Dr.<br \/>\n      Patrick Ott, Dana-Farber Cancer Institute \u2013 demonstrated an overall<br \/>\n      response rate (ORR) of 20 percent (confirmed and unconfirmed) (95% CI,<br \/>\n      6.8-40.7) and a disease control rate (DCR) of 64 percent (95% CI,<br \/>\n      42.5-82.0). Five partial responses (95% CI, 6.8-40.7) were observed, and<br \/>\n      44 percent of patients (n=11\/25) had stable disease (95% CI, 24.4-65.1).<br \/>\n      Additionally, the 6-month progression-free survival (PFS) rate was 31.6<br \/>\n      percent and the 12-month PFS rate was 19.7 percent. At the time of the<br \/>\n      analysis, response duration ranged from 0.1+ to 9.2+ months, with the<br \/>\n      median not yet reached. The median stable disease duration was 3.6<br \/>\n      months (range, 1.8+ to 11.0+).\n    <\/p>\n<p>\n      Adverse events were generally consistent with previously reported safety<br \/>\n      data for KEYTRUDA. Grade 3-4 investigator-assessed, treatment-related<br \/>\n      adverse events were thyroid-stimulating hormone increased (n=1), colitis<br \/>\n      (n=1), diarrhea (n=1), and general physical health deterioration (n=1).<br \/>\n      Immune-mediated adverse events were hypothyroidism (n=3) and colitis<br \/>\n      (n=1). There were no treatment-related deaths.\n    <\/p>\n<p>\n      <b>Early Findings from Advanced Biliary Tract Cancer (Abstract #525)<\/b>\n    <\/p>\n<p>\n      Early findings from 24 heavily pre-treated patients with advanced<br \/>\n      biliary tract cancer \u2013 presented in a poster session on Saturday, Sept.<br \/>\n      26 by Dr. Yung-Jue Bang, Seoul National University Hospital, Seoul,<br \/>\n      Korea \u2013 demonstrated an ORR of 17.4 percent (confirmed and unconfirmed)<br \/>\n      (95% CI, 5.0-38.8) (n=4\/23); 17.4 percent of patients had stable disease<br \/>\n      (95% CI, 5.0-38.8) (n=4\/23). As the time of the analysis, three of four<br \/>\n      responses were ongoing, and the median response duration had not yet<br \/>\n      been reached (range, 5.4+ to 9.3+ weeks).\n    <\/p>\n<p>\n      Adverse events were generally consistent with previously reported safety<br \/>\n      data for KEYTRUDA. Grade 3-4 investigator-assessed, treatment-related<br \/>\n      adverse events were anemia (n=1), autoimmune hemolytic anemia (n=1),<br \/>\n      colitis (n=1) and dermatitis (n=1). Immune-mediated adverse events were<br \/>\n      autoimmune hemolytic anemia (n=1), colitis (n=1), hypothyroidism (n=1),<br \/>\n      and hypothyroidism (n=1). There were no treatment-related deaths.\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><sup><b>\u00ae <\/b><\/sup><b>(pembrolizumab)<\/b>\n    <\/p>\n<p>\n      KEYTRUDA is a humanized monoclonal antibody that blocks the interaction<br \/>\n      between PD-1 and its ligands, PD-L1 and PD-L2. By binding to the PD-1<br \/>\n      receptor and blocking the interaction with the receptor ligands,<br \/>\n      KEYTRUDA releases the PD-1 pathway-mediated inhibition of the immune<br \/>\n      response, including the anti-tumor immune response. KEYTRUDA is<br \/>\n      indicated for the treatment of patients with unresectable or metastatic<br \/>\n      melanoma and disease progression following ipilimumab and, if BRAF V600<br \/>\n      mutation positive, a BRAF inhibitor. This indication is approved under<br \/>\n      accelerated approval based on tumor response rate and durability of<br \/>\n      response. An improvement in survival or disease-related symptoms has not<br \/>\n      yet been established. Continued approval for this indication may be<br \/>\n      contingent upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b>\n    <\/p>\n<p>\n      Pneumonitis occurred in 12 (2.9%) of 411 patients, including Grade 2 or<br \/>\n      3 cases in 8 (1.9%) and 1 (0.2%) patients, respectively, receiving<br \/>\n      KEYTRUDA. Monitor patients for signs and symptoms of pneumonitis.<br \/>\n      Evaluate suspected pneumonitis with radiographic imaging. Administer<br \/>\n      corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4<br \/>\n      pneumonitis.\n    <\/p>\n<p>\n      Colitis (including microscopic colitis) occurred in 4 (1%) of 411<br \/>\n      patients, including Grade 2 or 3 cases in 1 (0.2%) and 2 (0.5%)<br \/>\n      patients, respectively, receiving KEYTRUDA. Monitor patients for signs<br \/>\n      and symptoms of colitis. Administer corticosteroids for Grade 2 or<br \/>\n      greater colitis. Withhold KEYTRUDA for Grade 2 or 3; permanently<br \/>\n      discontinue KEYTRUDA for Grade 4 colitis.\n    <\/p>\n<p>\n      Hepatitis (including autoimmune hepatitis) occurred in 2 (0.5%) of 411<br \/>\n      patients, including a Grade 4 case in 1 (0.2%) patient, receiving<br \/>\n      KEYTRUDA. Monitor patients for changes in liver function. Administer<br \/>\n      corticosteroids for Grade 2 or greater hepatitis and, based on severity<br \/>\n      of liver enzyme elevations, withhold or discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Hypophysitis occurred in 2 (0.5%) of 411 patients, including a Grade 2<br \/>\n      case in 1 and a Grade 4 case in 1 (0.2% each) patient, receiving<br \/>\n      KEYTRUDA. Monitor patients for signs and symptoms of hypophysitis<br \/>\n      (including hypopituitarism and adrenal insufficiency). Administer<br \/>\n      corticosteroids for Grade 2 or greater hypophysitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; withhold or discontinue for Grade 3; and permanently<br \/>\n      discontinue KEYTRUDA for Grade 4 hypophysitis.\n    <\/p>\n<p>\n      Hyperthyroidism occurred in 5 (1.2%) of 411 patients, including Grade 2<br \/>\n      or 3 cases in 2 (0.5%) and 1 (0.2%) patients, respectively, receiving<br \/>\n      KEYTRUDA. Hypothyroidism occurred in 34 (8.3%) of 411 patients,<br \/>\n      including a Grade 3 case in 1 (0.2%) patient, receiving KEYTRUDA.<br \/>\n      Thyroid disorders can occur at any time during treatment. Monitor<br \/>\n      patients for changes in thyroid function (at the start of treatment,<br \/>\n      periodically during treatment, and as indicated based on clinical<br \/>\n      evaluation) and for clinical signs and symptoms of thyroid disorders.<br \/>\n      Administer corticosteroids for Grade 3 or greater hyperthyroidism.<br \/>\n      Withhold KEYTRUDA for Grade 3; permanently discontinue KEYTRUDA for<br \/>\n      Grade 4 hyperthyroidism. Isolated hypothyroidism may be managed with<br \/>\n      replacement therapy without treatment interruption and without<br \/>\n      corticosteroids.\n    <\/p>\n<p>\n      Type 1 diabetes mellitus, including diabetic ketoacidosis, has occurred<br \/>\n      in patients receiving KEYTRUDA. Monitor patients for hyperglycemia and<br \/>\n      other signs and symptoms of diabetes. Administer insulin for type 1<br \/>\n      diabetes, and withhold KEYTRUDA in cases of severe hyperglycemia until<br \/>\n      metabolic control is achieved.\n    <\/p>\n<p>\n      Nephritis occurred in 3 (0.7%) patients, consisting of one case of Grade<br \/>\n      2 autoimmune nephritis (0.2%) and two cases of interstitial nephritis<br \/>\n      with renal failure (0.5%), one Grade 3 and one Grade 4. Monitor patients<br \/>\n      for changes in renal function. Administer corticosteroids for Grade 2 or<br \/>\n      greater nephritis. Withhold KEYTRUDA for Grade 2; permanently<br \/>\n      discontinue KEYTRUDA for Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      Other clinically important immune-mediated adverse reactions can occur.<br \/>\n      The following clinically significant immune-mediated adverse reactions<br \/>\n      occurred in patients treated with KEYTRUDA: exfoliative dermatitis,<br \/>\n      uveitis, arthritis, myositis, pancreatitis, hemolytic anemia, partial<br \/>\n      seizures arising in a patient with inflammatory foci in brain<br \/>\n      parenchyma, severe dermatitis including bullous pemphigoid, myasthenic<br \/>\n      syndrome, optic neuritis, and rhabdomyolysis.\n    <\/p>\n<p>\n      For suspected immune-mediated adverse reactions, ensure adequate<br \/>\n      evaluation to confirm etiology or exclude other causes. Based on the<br \/>\n      severity of the adverse reaction, withhold KEYTRUDA and administer<br \/>\n      corticosteroids. Upon improvement of the adverse reaction to Grade 1 or<br \/>\n      less, initiate corticosteroid taper and continue to taper over at least<br \/>\n      1 month. Restart KEYTRUDA if the adverse reaction remains at Grade 1 or<br \/>\n      less. Permanently discontinue KEYTRUDA for any severe or Grade 3<br \/>\n      immune-mediated adverse reaction that recurs and for any<br \/>\n      life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      Infusion-related reactions, including severe and life-threatening<br \/>\n      reactions, have occurred in patients receiving KEYTRUDA. Monitor<br \/>\n      patients for signs and symptoms of infusion-related reactions including<br \/>\n      rigors, chills, wheezing, pruritus, flushing, rash, hypotension,<br \/>\n      hypoxemia, and fever. For severe or life-threatening reactions, stop<br \/>\n      infusion and permanently discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA may cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA was discontinued for adverse reactions in 9% of 411 patients.<br \/>\n      Adverse reactions, reported in at least two patients, that led to<br \/>\n      discontinuation of KEYTRUDA were: pneumonitis, renal failure, and pain.<br \/>\n      Serious adverse reactions occurred in 36% of patients. The most frequent<br \/>\n      serious adverse reactions, reported in 2% or more of patients, were<br \/>\n      renal failure, dyspnea, pneumonia, and cellulitis.\n    <\/p>\n<p>\n      The most common adverse reactions (reported in at least 20% of patients)<br \/>\n      were fatigue (47%), cough (30%), nausea (30%), pruritus (30%), rash<br \/>\n      (29%), decreased appetite (26%), constipation (21%), arthralgia (20%),<br \/>\n      and diarrhea (20%).\n    <\/p>\n<p>\n      The recommended dose of KEYTRUDA is 2 mg\/kg administered as an<br \/>\n      intravenous infusion over 30 minutes every three weeks until disease<br \/>\n      progression or unacceptable toxicity. No formal pharmacokinetic drug<br \/>\n      interaction studies have been conducted with KEYTRUDA. It is not known<br \/>\n      whether KEYTRUDA is excreted in human milk. Because many drugs are<br \/>\n      excreted in human milk, instruct women to discontinue nursing during<br \/>\n      treatment with KEYTRUDA. Safety and effectiveness of KEYTRUDA have not<br \/>\n      been established in pediatric patients.\n    <\/p>\n<p>\n      <b>Our Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck Oncology,<br \/>\n      helping people fight cancer is our passion and supporting accessibility<br \/>\n      to our cancer medicines is our commitment.&nbsp;Our focus is on pursuing<br \/>\n      research in immuno-oncology and we are accelerating every step in the<br \/>\n      journey \u2013 from lab to clinic \u2013 to potentially bring new hope to people<br \/>\n      with cancer. For more information about our oncology clinical trials,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51189226&amp;newsitemid=20150927005081&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=1&amp;md5=3ec94e7e2f222d35fa49fab03ef63a3e\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today\u2019s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to healthcare through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2F&amp;esheet=51189226&amp;newsitemid=20150927005081&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=b0600a3b61624aafb6e399c072a99201\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Fmerck&amp;esheet=51189226&amp;newsitemid=20150927005081&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=ca8283eb820682ad3c50653b0a8a04ed\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51189226&amp;newsitemid=20150927005081&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=bde4cb8632d5066b9be3f756cd5cff07\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.youtube.com%2Fuser%2FMerck&amp;esheet=51189226&amp;newsitemid=20150927005081&amp;lan=en-US&amp;anchor=YouTube&amp;index=5&amp;md5=790c94ca85e3bc5e3a29fdc0df98633d\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include, but are not limited to, general<br \/>\n      industry conditions and competition; general economic factors, including<br \/>\n      interest rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and healthcare legislation in the<br \/>\n      United States and internationally; global trends toward healthcare cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2014 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51189226&amp;newsitemid=20150927005081&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=6&amp;md5=f8f9ce7ac4c467b20e8971dbff38323d\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51189226&amp;newsitemid=20150927005081&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=7&amp;md5=c1c8873d406a289856b21af816e5118a\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><\/a><b><br \/>\n      and the Medication Guide for KEYTRUDA at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51189226&amp;newsitemid=20150927005081&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=8&amp;md5=b14c53ff2f24348b2d4a911497db8de9\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><\/a>\n    <\/p>\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150927005081r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media Contacts:<br \/>Pamela Eisele, 267-305-3558<br \/>An        Phan, 908-255-6325<br \/>or<br \/>Investor Contacts:<br \/>Teri Loxam,        908-740-1986<br \/>Justin Holko, 908-740-1879     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced new findings from the KEYNOTE-028 Phase 1b study, the clinical trial investigating the use of the company\u2019s anti-PD-1 therapy, KEYTRUDA \u00ae (pembrolizumab) in multiple, difficult-to-treat cancers. Data from this trial, to be presented at the European Cancer Congress (ECC) in Vienna, Austria, Sept. 25-29, include the first-time findings for KEYTRUDA in two gastrointestinal cancers, advanced anal cancer and advanced biliary tract cancer, and add to Merck\u2019s growing body of clinical data for KEYTRUDA. KEYNOTE-028 is an ongoing multi-cohort, non-randomized Phase 1b basket trial \u2013 a trial design that allows for the study of multiple sub-populations of different tumor or histological types within one study. The study is evaluating the safety, tolerability, and anti-tumor activity of KEYTRUDA monotherapy (10 mg\/kg dosed every two weeks) in more than 450 patients across 20 different types of cancer. The study<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,138,55,289,56],"class_list":["post-745114","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-oncology-newsroom","tag-prescription-medicine-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>New Data from KEYNOTE-028, Merck\u2019s Trial Evaluating KEYTRUDA\u00ae (pembrolizumab) Across a Range of Cancer Types, Presented at 2015 European Cancer Congress - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-data-from-keynote-028-mercks-trial-evaluating-keytruda-pembrolizumab-across-a-range-of-cancer-types-presented-at-2015-european-cancer-congress\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New Data from KEYNOTE-028, Merck\u2019s Trial Evaluating KEYTRUDA\u00ae (pembrolizumab) Across a Range of Cancer Types, Presented at 2015 European Cancer Congress - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced new findings from the KEYNOTE-028 Phase 1b study, the clinical trial investigating the use of the company\u2019s anti-PD-1 therapy, KEYTRUDA \u00ae (pembrolizumab) in multiple, difficult-to-treat cancers. Data from this trial, to be presented at the European Cancer Congress (ECC) in Vienna, Austria, Sept. 25-29, include the first-time findings for KEYTRUDA in two gastrointestinal cancers, advanced anal cancer and advanced biliary tract cancer, and add to Merck\u2019s growing body of clinical data for KEYTRUDA. KEYNOTE-028 is an ongoing multi-cohort, non-randomized Phase 1b basket trial \u2013 a trial design that allows for the study of multiple sub-populations of different tumor or histological types within one study. The study is evaluating the safety, tolerability, and anti-tumor activity of KEYTRUDA monotherapy (10 mg\/kg dosed every two weeks) in more than 450 patients across 20 different types of cancer. The study\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-data-from-keynote-028-mercks-trial-evaluating-keytruda-pembrolizumab-across-a-range-of-cancer-types-presented-at-2015-european-cancer-congress\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:24:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-data-from-keynote-028-mercks-trial-evaluating-keytruda-pembrolizumab-across-a-range-of-cancer-types-presented-at-2015-european-cancer-congress\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-data-from-keynote-028-mercks-trial-evaluating-keytruda-pembrolizumab-across-a-range-of-cancer-types-presented-at-2015-european-cancer-congress\\\/\",\"name\":\"New Data from KEYNOTE-028, Merck\u2019s Trial Evaluating KEYTRUDA\u00ae (pembrolizumab) Across a Range of Cancer Types, Presented at 2015 European Cancer Congress - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2015-09-27T06:00:00+00:00\",\"dateModified\":\"2025-11-07T06:24:55+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-data-from-keynote-028-mercks-trial-evaluating-keytruda-pembrolizumab-across-a-range-of-cancer-types-presented-at-2015-european-cancer-congress\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-data-from-keynote-028-mercks-trial-evaluating-keytruda-pembrolizumab-across-a-range-of-cancer-types-presented-at-2015-european-cancer-congress\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-data-from-keynote-028-mercks-trial-evaluating-keytruda-pembrolizumab-across-a-range-of-cancer-types-presented-at-2015-european-cancer-congress\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New Data from KEYNOTE-028, Merck\u2019s Trial Evaluating KEYTRUDA\u00ae (pembrolizumab) Across a Range of Cancer Types, Presented at 2015 European Cancer Congress\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"New Data from KEYNOTE-028, Merck\u2019s Trial Evaluating KEYTRUDA\u00ae (pembrolizumab) Across a Range of Cancer Types, Presented at 2015 European Cancer Congress - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-data-from-keynote-028-mercks-trial-evaluating-keytruda-pembrolizumab-across-a-range-of-cancer-types-presented-at-2015-european-cancer-congress\/","og_locale":"en_US","og_type":"article","og_title":"New Data from KEYNOTE-028, Merck\u2019s Trial Evaluating KEYTRUDA\u00ae (pembrolizumab) Across a Range of Cancer Types, Presented at 2015 European Cancer Congress - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced new findings from the KEYNOTE-028 Phase 1b study, the clinical trial investigating the use of the company\u2019s anti-PD-1 therapy, KEYTRUDA \u00ae (pembrolizumab) in multiple, difficult-to-treat cancers. Data from this trial, to be presented at the European Cancer Congress (ECC) in Vienna, Austria, Sept. 25-29, include the first-time findings for KEYTRUDA in two gastrointestinal cancers, advanced anal cancer and advanced biliary tract cancer, and add to Merck\u2019s growing body of clinical data for KEYTRUDA. KEYNOTE-028 is an ongoing multi-cohort, non-randomized Phase 1b basket trial \u2013 a trial design that allows for the study of multiple sub-populations of different tumor or histological types within one study. The study is evaluating the safety, tolerability, and anti-tumor activity of KEYTRUDA monotherapy (10 mg\/kg dosed every two weeks) in more than 450 patients across 20 different types of cancer. The study","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-data-from-keynote-028-mercks-trial-evaluating-keytruda-pembrolizumab-across-a-range-of-cancer-types-presented-at-2015-european-cancer-congress\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:24:55+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-data-from-keynote-028-mercks-trial-evaluating-keytruda-pembrolizumab-across-a-range-of-cancer-types-presented-at-2015-european-cancer-congress\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-data-from-keynote-028-mercks-trial-evaluating-keytruda-pembrolizumab-across-a-range-of-cancer-types-presented-at-2015-european-cancer-congress\/","name":"New Data from KEYNOTE-028, Merck\u2019s Trial Evaluating KEYTRUDA\u00ae (pembrolizumab) Across a Range of Cancer Types, Presented at 2015 European Cancer Congress - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2015-09-27T06:00:00+00:00","dateModified":"2025-11-07T06:24:55+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-data-from-keynote-028-mercks-trial-evaluating-keytruda-pembrolizumab-across-a-range-of-cancer-types-presented-at-2015-european-cancer-congress\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-data-from-keynote-028-mercks-trial-evaluating-keytruda-pembrolizumab-across-a-range-of-cancer-types-presented-at-2015-european-cancer-congress\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-data-from-keynote-028-mercks-trial-evaluating-keytruda-pembrolizumab-across-a-range-of-cancer-types-presented-at-2015-european-cancer-congress\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"New Data from KEYNOTE-028, Merck\u2019s Trial Evaluating KEYTRUDA\u00ae (pembrolizumab) Across a Range of Cancer Types, Presented at 2015 European Cancer Congress"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"b07aa90d-3a23-493f-ae6e-e8f160874b5c","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/New-Data-from-KEYNOTE-028-Mercks-Trial-Evaluating-KEYTRUDA-pembrolizumab-Across-a-Range-of-Cancer-Types-Presented-at-2015-European-Ca-M7MU6.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745114","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745114\/revisions"}],"predecessor-version":[{"id":3674595,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745114\/revisions\/3674595"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745114"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745114"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}